AGENUS INC
No SEC Form 4 filings for $AGEN in the last 30 days.
See all $AGEN insider activity →Agenus Inc. reported Phase 2 NEOASIS study results, showing 83% MPR and 72% pCR in 18 dMMR colon cancer patients treated with botensilimab plus balstilimab. The company aims to expand use across tumors, pending further studies and regulatory discussions.
Chardan Capital kept its Buy rating on Agenus with a $40 price target, implying a 525% upside from the Oct 21 close. The firm cited Agenus's strong development pipeline, including botensilimab and balstilimab, and positive clinical data expectations from studies like NEST and UNICORN.
Agenus (AGEN) plans a Phase III trial for BOT/BAL in colon cancer, with interim data expected in 2H 2029. The study targets a 35% improvement in recurrence risk. The 60th patient enrollment in 2Q 2027 could unlock $85M in funding. Early data show promising responses, but long-term efficacy is uncertain. Agenus continues access programs for metastatic cancer patients.
Over the past 7 days, AlphAI's AI scored 8 news stories mentioning AGEN (AGENUS INC). Coverage has skewed bullish: 8 bullish, 0 neutral, and 0 bearish.
Recent AGEN coverage spans financial news, corporate actions and regulation.
Positive early‑stage data could lift the stock on expectations of later‑stage success.
Analyst upgrade with a high price target may drive buying interest.
Long‑term clinical milestone with potential future upside, but no immediate price catalyst.
The approval opens a new market and may drive near‑term share price appreciation.
Analyst upgrade and high price target may drive buying pressure.
AlphAI scores every news story that mentions AGEN with an AI model for sentiment and relevance, and aggregates insider trades from AGENUS INC's SEC EDGAR Form 4 filings. Figures refresh continuously.
Agenus Inc. reported Phase 2 NEOASIS study results, showing 83% MPR and 72% pCR in 18 dMMR colon cancer patients treated with botensilimab plus balstilimab. The company aims to expand use across tumors, pending further studies and regulatory discussions.
1 min readChardan Capital kept its Buy rating on Agenus with a $40 price target, implying a 525% upside from the Oct 21 close. The firm cited Agenus's strong development pipeline, including botensilimab and balstilimab, and positive clinical data expectations from studies like NEST and UNICORN.
1 min readAgenus (AGEN) plans a Phase III trial for BOT/BAL in colon cancer, with interim data expected in 2H 2029. The study targets a 35% improvement in recurrence risk. The 60th patient enrollment in 2Q 2027 could unlock $85M in funding. Early data show promising responses, but long-term efficacy is uncertain. Agenus continues access programs for metastatic cancer patients.
1 min readAgenus Inc. (AGEN) announced that Armenia's Ministry of Health approved Botvymo and Evamplix for treating specific colorectal cancer patients. The approvals, effective October 2, are based on clinical studies and are valid for one year. Agenus plans to evaluate authorizations in other Eurasian Economic Union countries. The drugs are also available in France and other countries through specific programs.
2 min readChardan Capital kept its Buy rating on Agenus with a $40 price target, implying a 378.5% upside from the Oct 2 close of $8.36. The firm cited durable patient outcomes and positive clinical signals in challenging subgroups for the BOT+BAL treatment.
1 min readAgenus reported 48% three-year overall survival in 35 patients from its Phase 1b ovarian cancer trial using botensilimab plus balstilimab. 25% of 44 treated patients were alive and off therapy at last follow-up. The results extend earlier Phase 1b signals, suggesting durability for the combination.
1 min readChardan Capital initiated coverage of Agenus (AGEN) with a Buy rating and $40 price target, implying 454% upside from the Sep 17 close of $7.22. The firm highlights strong clinical data for Agenus's immunotherapy candidates, BOT and BAL, in treating MSS colorectal cancer, and the company's strategic focus on an unmet medical need.
1 min readBenzinga reports unusual options activity in 10 healthcare stocks. Notable trades include bullish calls on SELLAS Life Sciences (SLS) at $30 strike, bearish calls on Zoetis (ZTS) at $85 strike, and bullish puts on Lilly (LLY) at $1260 strike. Other stocks with notable activity include NBIX, AGEN, BBIO, BSX, NVO, and CAPR.
2 min readAgenus' unit has entered a second loan modification agreement with Ocean 1181, according to an SEC filing. The agreement is set to take effect on August 12, 2026.
1 min readAGENUS INC (AGEN) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. On August 12, 2026, Agenus West, LLC (the “Borrower”), a subsidiary of Agenus Inc. (the “Company”), and the Company, as guarantor, entered into a Second Loan Modification Agreement (the “Loan Modification Agreement”) with Ocea
4 min read
